image
Conservation

Compilation of herbal plants (description, geographical distribution, taxonomy, line drawings), biodiversity and herbarium.

Read More
image
Research & Publication

Description of herbal and T&CM research, searchable publication and process from medicinal plant discovery to clinical trial in producing a high-quality registered herbal drug.

Read More
 
Traditional & Complementary Medicine (T&CM)

 

Definition and description of therapies, policy, training and education, research in the practise of (T&CM) and integrated medicine system.           

Read More

 

News Update

Announcement & Advertisement

Forthcoming Events

International Conference on Biotechnology and Healthcare

From Mon, 7. December 2020 Until Tue, 8. December 2020

International Conference on Malay Medical Manuscript

From Tue, 15. December 2020 Until Wed, 16. December 2020

International Conference on Natural Medicine and Nutrition (ICNMN) 2020

From Thu, 17. December 2020 Until Fri, 18. December 2020

1st Global Summit on Generic Drugs and Quality Control

From Fri, 22. January 2021 Until Sat, 23. January 2021

International Conference on Natural Products and Drug Discovery (ICNPDD) 2021

From Thu, 11. February 2021 Until Fri, 12. February 2021

Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline

Author

Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al.

Date

10/2002

Journal

Arch Neurol

Abstract

BACKGROUND: Parkinson disease (PD) is a degenerative neurological disorder for which no treatment has been shown to slow the progression. OBJECTIVE: To determine whether a range of dosages of coenzyme Q(10) is safe and well tolerated and could slow the functional decline in PD. DESIGN: Multicenter, randomized, parallel-group, placebo-controlled, double-blind, dosage-ranging trial. SETTING: Academic movement disorders clinics. PATIENTS: Eighty subjects with early PD who did not require treatment for their disability. INTERVENTIONS: Random assignment to placebo or coenzyme Q(10) at dosages of 300, 600, or 1200 mg/d. MAIN OUTCOME MEASURE: The subjects underwent evaluation with the Unified Parkinson Disease Rating Scale (UPDRS) at the screening, baseline, and 1-, 4-, 8-, 12-, and 16-month visits. They were followed up for 16 months or until disability requiring treatment with levodopa had developed. The primary response variable was the change in the total score on the UPDRS from baseline to the last visit. RESULTS: The adjusted mean total UPDRS changes were +11.99 for the placebo group, +8.81 for the 300-mg/d group, +10.82 for the 600-mg/d group, and +6.69 for the 1200-mg/d group. The P value for the primary analysis, a test for a linear trend between the dosage and the mean change in the total UPDRS score, was.09, which met our prespecified criteria for a positive trend for the trial. A prespecified, secondary analysis was the comparison of each treatment group with the placebo group, and the difference between the 1200-mg/d and placebo groups was significant (P =.04). CONCLUSIONS: Coenzyme Q(10) was safe and well tolerated at dosages of up to 1200 mg/d. Less disability developed in subjects assigned to coenzyme Q(10 ) than in those assigned to placebo, and the benefit was greatest in subjects receiving the highest dosage. Coenzyme Q(10) appears to slow the progressive deterioration of function in PD, but these results need to be confirmed in a larger study.

Explore Further

Consumer Data

Consumer data including medicinal herbs, dietary supplement monographs, health condition monographs and interactions and depletions.                                    

Read More
Professional Data

Professional data organized into medicinal herbs, dietary supplement monographs, health condition monographs, T&CM herbs, formulas, health conditions, interactions and depletions.

Read More
International Data

We offer International linkages to provide extensive content pertaining to many facets of T&CM as well as Integrated Medicine. Please register for access.    

Read More